ProCE Banner Activity

Key Leukemia Trials From ASH 2019: A European Perspective

Conference Coverage
Clinical Thought
Michael Heuser, MD, provides his thoughts on key studies in leukemias presented at ASH 2019 and their potential implications for practice in Europe.

Released: January 24, 2020

Expiration: January 22, 2021

Share

Faculty

Michael Heuser

Michael Heuser, MD

Chair for Molecular Therapies in Hematology
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Hannover, Germany

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Gilead

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Michael Heuser, MD

Chair for Molecular Therapies in Hematology
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Hannover, Germany

Michael Heuser, MD, has disclosed that he has received consulting fees from AbbVie, Bayer Pharma AG, Daiichi Sankyo, Novartis, and Pfizer and funds for research support from Astellas, Bayer Pharma AG, BerGenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, and Roche.